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Abstract
The antiphospholipid syndrome is an autoimmune disease characterised by recurrent arterial or
venous thrombosis, pregnancy morbidity and the persistence of positive antiphospholipid
antibodies. Many other clinical manifestations may occur including heart valve disease, livedo
reticularis, thrombocytopenia and neurological manifestations such as migraine and seizures. We
review a number of other manfestations including stenotic lesions, coronary artery disease and
accelerated atherosclerosis, skeletal disorders and the concept of seronegative antiphospholipid
syndrome.
Introduction
The antiphospholipid (Hughes) syndrome (APS), first
described in 1983, is an autoimmune disease character-
ised by recurrent arterial or venous thrombosis, pregnancy
morbidity and the persistence of positive antiphospholi-
pid antibodies (aPL) [1]. Although only thrombosis and
pregnancy loss are included in the revised classification
criteria for APS [2], other features are also described [3].
These include heart valve disease, livedo reticularis,
thrombocytopenia and neurological manifestations such
as migraine and seizures. Recently a number of other fea-
tures have been described in APS, which we discuss in this
review.
Stenotic lesions and vasculopathy
Vascular occlusions are increasingly being recognized in
patients with APS, although the exact etiology remains
unclear [4]. We found a high prevalence of renal artery ste-
nosis (RAS) in APS patients with uncontrolled hyperten-
sion compared to two control groups [5]. Other stenotic
lesions such as coeliac [6] and intracerebral arterial steno-
sis [7] have also been reported. These stenotic lesions are
smooth and well defined and are different from those
seen in atherosclerotic RAS or fibromuscular dysplasia [5].
Interestingly histological examination in SLE patients
with APS [8] and a case report of a resected superior
mesenteric artery showed fibro-elastic thickening of the
intima and thrombosis [9]. These findings suggest that
thrombosis and intimal and smooth muscle hyperplasia
may be responsible for the vasculopathy in APS. Prelimi-
nary reports suggest that anticoagulation with a high
intensity international normalized ratio (INR) helps to
control blood pressure and prevents re-stenosis in APS
patients with RAS [10]. Similarly, other case reports
emphasize the importance of high intensity INR in vari-
ous stenotic lesions in APS patients [7,11,12].
Coronary artery disease
Since the description of the APS syndrome, a number of
cardiac manifestations have been described including car-
diac valvular abnormalities (Libman-Sacks endocarditis)
[13,14]. Coronary artery disease in young adults and cor-
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onary artery bypass graft occlusions have been reported in
APS patients [15]. Although typical myocardial infarction
(MI) is well described in patients with APS [16,17], a
number of reports have described MI and so called Syn-
drome X in the absence of atherosclerotic obstructive cor-
onary artery lesions [18-20]. Cardiac Syndrome X is
defined by the presence of angina-like chest pain, a posi-
tive response to stress testing and normal coronary arteri-
ograms. Syndrome X is seen in menopausal women [21]
and so was linked to low oestrogen levels [22]. However,
in APS patients, Syndrome X and MI were observed in
young women who were not menopausal [23]. His-
topathological findings in myocardial tissue of a patient
with APS, showed a non-inflammatory micro-vasculopa-
thy, characterized by thrombi, and further ultra-structural
studies confirmed the thrombosis and demonstrated
endothelial activation [24]. These findings support the
hypothesis that the endothelial dysfunction and subse-
quent thrombosis seen in the APS patients may be respon-
sible for Syndrome X/MI and argues against the lack of
oestrogen theory. Experts in this field recommend long
term anticoagulation in this group of patients [19,20].
Cerebral manifestations
Although stroke is the only accepted neurological crite-
rion for the diagnosis of APS, a number of other manifes-
tations are observed in the APS. The spectrum of non-
thrombotic cerebral manifestations may range from focal
neurological lesions to diffuse global dysfunction. It
includes severe headaches, often migranous, hemiplegic
migraine, cognitive dysfunction and memory deficits, dys-
phasia (mixing or inappropriate words), behavioural
changes and seizure disorders [25]. Extrapyramidal symp-
toms such as chorea have also been described in associa-
tion with sub-cortical dementia in patients with APS [26].
Tektonidou et al noted a significant association between
cognitive dysfunction and white matter lesions in the
brain in patients with APS [27]. It is not uncommon to see
white matter changes in the brain mimicking multiple
sclerosis. Although a double blind cross-over trial com-
paring low molecular weight heparin with placebo failed
to show positive results [28], clinical experience suggests
that severe cognitive dysfunction and intractable head-
aches often respond to anticoagulation therapy in these
patients [25].
Skeletal manifestations of the APS
APS may involve multiple organs such as kidney, brain,
eye, ear and liver and it may also affect the skeleton. A pro-
spective cohort study [29] together with several case
reports of osteonecrosis in primary APS in the absence of
osteoporosis [30,31], have strengthened the possible
association between aPL and osteonecrosis. Our own
experience is that non-traumatic metatarsal fractures are
more prevalent in APS/aPL positive patients [32,33].
Interestingly most had normal DEXA scans, none had any
preceding trauma and none had received high doses of
steroids. To assess the true prevalence of these fractures
and their relation to aPL, a prospective study is needed in
both symptomatic and asymptomatic patients.
Endothelial dysfunction
Accelerated atheroma has been described as a feature of
APS as in other autoimmune inflammatory conditions.
APS/aPL are associated with accelerated atherosclerosis
[34] by targeting some of the steps that constitute early
atherogenesis from endothelial activation to oxidized
LDL uptake by foam macrophages [35,36]. The ankle-bra-
chial index (ABI) was found to be abnormal in patients
with APS with thrombosis as well as in APS patients with
pregnancy morbidity without thrombosis [37,38]. A
recent study by Charakida et al of endothelial assessment
in patients with APS is worth mentioning. She studied 90
age, sex and cardiovascular risk factor profile matched
patients with primary APS and a control group of 90 peo-
ple with negative aPL. High resolution ultrasound was
used to determine carotid intima media thickness (cIMT),
endothelium dependent flow mediated dilatation (FMD)
and endothelium independent nitroglycerine mediated
dilatation of the brachial artery. This data showed signifi-
cantly reduced FMD and increased cIMT in APS patients as
compared to healthy individuals [39]. This corroborates
previous observations by Medina et al [40]. Similarly,
observations by Ames et al of subclinical atherosclerosis
using intima-medial thickness in patients with primary
APS in their 4th decade are worth mentioning [41]. This
data indicates that endothelial dysfunction and pre-clini-
cal atherosclerosis is prevalent in APS/aPL patients. The
increased prevalence of an abnormal ABI in patients with
APS, suggests that a large vessel vasculopathy could be a
contributing factor to both thrombosis and pregnancy
loss in APS [37,38].
Complications following renal biopsy in patients 
with APS/aPL
Although APS is by definition a hypercoaguable state, a
surprising recent preliminary report by Chaib et al found
an increased risk of bleeding complications following
renal biopsy in patients with lupus nephritis (LN) and
APS/aPL as compared to LN alone [42]. This single centre
study examined > 200 patients of which 86 were APS/aPL
positive. The study identified a positive lupus anticoagu-
lant and elevated serum creatinine levels as significant risk
factors for post biopsy bleeding complications.
Livedo reticularis and "Seronegative APS"
"Sero-negative" APS has remained an enigma and the con-
cept is controversial. According to classification criteria for
APS, aPL (lupus anticoagulant and anticardiolipin anti-
bodies) and Beta 2 Glycoprotein I (B2GPI) antibodies areJournal of Autoimmune Diseases 2009, 6:3 http://www.jautoimdis.com/content/6/1/3
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essential for the classification of patients with APS.
Although aPL and anti-B2GPI are sensitive tests, they are
not sensitive enough to pick up all patients with APS. A
small group of APS patients remain persistently negative
for routine assays of aPL [43,44]. Livedo reticularis was
included in the original clinical description of the APS.
Frances et al reported significant associations between
pathological livedo reticularis (racemosa) and cerebral or
ocular ischemic arterial events, seizures, heart valve
abnormalities, hypertension and Raynaud's phenomenon
in patients with APS [45]. As with APS, livedo reticularis
in the absence of aPL has been associated with pregnancy
morbidity and abnormal ABI [46]. Livedo reticularis
shares a number of features with APS such as pregnancy
loss, arterial thrombosis, heart valve abnormalities and
seizures [47] and indeed it is the most common cutaneous
manifestation of APS [48,49]. There is therefore increas-
ing evidence that "seronegative" APS does exist and it may
be that serological markers other than aPL and anti-B2GPI
are important in these patients. Pathological livedo retic-
ularis may therefore be a clinical marker of the "seronega-
tive APS" [46,50].
Conclusion
The spectrum of APS is not limited to thrombosis or preg-
nancy morbidity and clinicians should be aware of the
broad range of manifestations with multi-system involve-
ment.
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